On the other hand, metformin, a first-line therapy for type 2 diabetes mellitus, activates AMPK indirectly by increasing the AMP/ATP ratio, thereby enhancing insulin sensitivity and reducing hepatic glucose production [76]. The gene discussed is INS; the disease is type 2 diabetes mellitus.